Donor t cells aim to block virus after transplant
NCT ID NCT07476014
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether specially prepared immune cells from a donor can prevent Epstein-Barr virus (EBV) infection in people who have received a stem cell transplant. About 9 to 18 participants will receive the cells and be monitored for side effects and infection. The goal is to find a safe and effective way to protect high-risk patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREVENTION OF EBV INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.